Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathways

Journal of Neurochemistry

Volumn 105, Issue 5, 2008, Pages 1700-1715

  Hasegawa, Takafumi ^a   Treis, Angela ^a   Patenge, Nadja ^a   Fiesel, Fabienne C ^a   Springer, Wolfdieter ^a   Kahle, Philipp J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; Dopamine; Neurotoxicity; Parkin; Stress activated protein kinases; Tyrosinase

Indexed keywords

4 BP; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; DOPAMINE; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOPHENOL MONOOXYGENASE; MUTANT PROTEIN; PARKIN; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; UBIQUITIN PROTEIN LIGASE;

AEROBIC METABOLISM; APOPTOSIS; ARTICLE; BRAIN PROTECTION; CELL CULTURE; CONTROLLED STUDY; CYTOSOL; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE; NEUROBLASTOMA CELL; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRIATONIGRAL DEGENERATION;

EID: 43549122572     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05277.x     Document Type: Article

References (66)

1. Abeliovich A. and Beal M. F. (2006) Parkinsonism genes: culprits and clues. J. Neurochem. 99, 1062–1072.
2. Ardley H. C., Scott G. B., Rose S. A., Tan N. G. S., Markham A. F. and Robinson P. A. (2003) Inhibition of proteasomal activity causes inclusion formation in neuronal and non‐neuronal cells overexpressing Parkin. Mol. Biol. Cell 14, 4541–4556.
3. Asanuma M., Miyazaki I. and Ogawa N. (2003) Dopamine‐ or L‐DOPA‐induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox. Res. 5, 165–176.
4. Avraham E., Rott R., Liani E., Szargel R. and Engelender S. (2007) Phosphorylation of Parkin by the cyclin‐dependent kinase 5 at the linker region modulates its ubiquitin‐ligase activity and aggregation. J. Biol. Chem. 282, 12842–12850.
5. Cha G.‐H., Kim S., Park J., Lee E., Kim M., Lee S. B., Kim J. M., Chung J. and Cho K. S. (2005) Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc. Natl Acad. Sci. USA 102, 10345–10350.
6. Chung K. K. K., Thomas B., Li X., Pletnikova O., Troncoso J. C., Marsh L., Dawson V. L. and Dawson T. M. (2004) S ‐nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science 304, 1328–1331.
7. Cookson M. R., Lockhart P. J., McLendon C., O’Farrell C., Schlossmacher M. and Farrer M. J. (2003) RING finger 1 mutations in Parkin produce altered localization of the protein. Hum. Mol. Genet. 12, 2957–2965.
8. Corti O., Hampe C., Koutnikova H. et al. (2003) The p38 subunit of the aminoacyl‐tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum. Mol. Genet. 12, 1427–1437.
9. Darios F., Corti O., Lücking C. B. et al. (2003) Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria‐dependent cell death. Hum. Mol. Genet. 12, 517–526.
10. Fallon L., Bélanger C. M. L., Corera A. T. et al. (2006) A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K‐Akt signalling. Nat. Cell Biol. 8, 834–842.
11. Gómez‐Santos C., Ferrer I., Santidrián A. F., Barrachina M., Gil J. and Ambrosio S. (2003) Dopamine induces autophagic cell death and α‐synuclein increase in human neuroblastoma SH‐SY5Y cells. J. Neurosci. Res. 73, 341–350.
12. Greggio E., Bergantino E., Carter D. et al. (2005) Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson’s disease. J. Neurochem. 93, 246–256.
13. Gu W.‐J., Corti O., Araujo F. et al. (2003) The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates. Neurobiol. Dis. 14, 357–364.
14. Hampe C., Ardila‐Osorio H., Fournier M., Brice A. and Corti O. (2006) Biochemical analysis of Parkinson’s disease‐causing variants of Parkin, an E3 ubiquitin‐protein ligase with monoubiquitylation capacity. Hum. Mol. Genet. 15, 2059–2075.
15. Hasegawa T., Matsuzaki M., Takeda A., Kikuchi A., Furukawa K., Shibahara S. and Itoyama Y. (2003) Increased dopamine and its metabolites in SH‐SY5Y neuroblastoma cells that express tyrosinase. J. Neurochem. 87, 470–475.
16. Hasegawa T., Matsuzaki‐Kobayashi M., Takeda A., Sugeno N., Kikuchi A., Furukawa K., Perry G., Smith M. A. and Itoyama Y. (2006) α‐synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson’s disease. FEBS Lett. 580, 2147–2152.
17. Hasegawa T., Sugeno N., Takeda A., Matsuzaki‐Kobayashi M., Kikuchi A., Furukawa K., Miyagi T. and Itoyama Y. (2007) Role of Neu4L sialidase and its substrate ganglioside GD3 in neuronal apoptosis induced by catechol metabolites. FEBS Lett. 581, 406–412.
18. Haywood A. F. M. and Staveley B. E. (2006) Mutant α‐synuclein‐ induced degeneration is reduced by parkin in a fly model of Parkinson’s disease. Genome 49, 505–510.
19. Henn I. H., Gostner J. M., Lackner P., Tatzelt J. and Winklhofer K. F. (2005) Pathogenic mutations inactivate parkin by distinct mechanisms. J. Neurochem. 92, 114–122.
20. Henn I. H., Bouman L., Schlehe J. S. et al. (2007) Parkin mediates neuroprotection through activation of IκB kinase/nuclear factor‐κB signaling. J. Neurosci. 27, 1868–1878.
21. Higashi Y., Asanuma M., Miyazaki I., Hattori N., Mizuno Y. and Ogawa N. (2004) Parkin attenuates manganese‐induced dopaminergic cell death. J. Neurochem. 89, 1490–1497.
22. Huynh D. P., Nguyen D. T., Pulst‐Korenberg J. B., Brice A. and Pulst S.‐M. (2007) Parkin is an E3 ubiquitin‐ligase for normal and mutant ataxin‐2 and prevents ataxin‐2‐induced cell death. Exp. Neurol. 203, 531–541.
23. Hyun D.‐H., Lee M., Halliwell B. and Jenner P. (2005) Effect of overexpression of wild‐type or mutant parkin on the cellular response induced by toxic insults. J. Neurosci. Res. 82, 232–244.
24. Imai Y., Soda M. and Takahashi R. (2000) Parkin suppresses unfolded protein stress‐induced cell death through its E3 ubiquitin‐protein ligase activity. J. Biol. Chem. 275, 35661–35664.
25. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y. and Takahashi R. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 891–902.
26. Jensen L. D., Vinther‐Jensen T., Kahns S., Sundbye S. and Jensen P. H. (2006) Cellular parkin mutants are soluble under non‐stress conditions. NeuroReport 17, 1205–1208.
27. Jiang H., Ren Y., Zhao J. and Feng J. (2004) Parkin protects human dopaminergic neuroblastoma cells against dopamine‐induced apoptosis. Hum. Mol. Genet. 13, 1745–1754.
28. Jimbow K., Park J. S., Kato F., Hirosaki K., Toyofuku K., Hua C. and Yamashita T. (2000) Assembly, target‐signaling and intracellular transport of tyrosinase gene family proteins in the initial stage of melanosome biogenesis. Pigment Cell Res. 13, 222–229.
29. Junn E. and Mouradian M. M. (2001) Apoptotic signaling in dopamine‐induced cell death: the role of oxidative stress, p38 mitogen‐activated protein kinase, cytochrome c and caspases. J. Neurochem. 78, 374–383.
30. Kahle P. J. and Haass C. (2004) How does parkin ligate ubiquitin to Parkinson’s disease? EMBO Rep. 5, 681–685.
31. Kim Y. J., No J. K., Lee J. H. and Chung H. Y. (2005) 4,4′‐Dihydroxybiphenyl as a new potent tyrosinase inhibitor. Biol. Pharm. Bull. 28, 323–327.
32. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. and Shimizu N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605–608.
33. Ko H. S., Von Coelln R., Sriram S. R. et al. (2005) Accumulation of the authentic parkin substrate aminoacyl‐tRNA synthetase cofactor, p38/JTV‐1, leads to catecholaminergic cell death. J. Neurosci. 25, 7968–7978.
34. Kyratzi E., Pavlaki M., Kontostavlaki D., Rideout H. J. and Stefanis L. (2007) Differential effects of Parkin and its mutants on protein aggregation, the ubiquitin‐proteasome system, and neuronal cell death in human neuroblastoma cells. J. Neurochem. 102, 1292–1303.
35. LaVoie M. J., Ostaszewski B. L., Weihofen A., Schlossmacher M. G. and Selkoe D. J. (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11, 1214–1221.
36. LaVoie M. J., Cortese G. P., Ostaszewski B. L. and Schlossmacher M. G. (2007) The effects of oxidative stress on parkin and other E3 ligases. J. Neurochem. 103, 2354–2368.
37. Lim K.‐L., Dawson V. L. and Dawson T. M. (2006) Parkin‐mediated lysine 63‐linked polyubiquitination: a link to protein inclusions formation in Parkinson’s and other conformational diseases? Neurobiol. Aging 27, 524–529.
38. Lo Bianco C., Schneider B. L., Bauer M., Sajadi A., Brice A., Iwatsubo T. and Aebischer P. (2004) Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α‐synuclein rat model of Parkinson’s disease. Proc. Natl Acad. Sci. USA 101, 17510–17515.
39. Mata I. F., Lockhart P. J. and Farrer M. J. (2004) Parkin genetics: one model for Parkinson’s disease. Hum. Mol. Genet. 13 (Suppl. 1), R127–R133.
40. Muqit M. M. K., Davidson S. M., Payne Smith M. D., MacCormac L. P., Kahns S., Jensen P. H., Wood N. W. and Latchman D. S. (2004) Parkin is recruited into aggresomes in a stress‐specific manner: over‐expression of parkin reduces aggresome formation but can be dissociated from parkin’s effect on neuronal survival. Hum. Mol. Genet. 13, 117–135.
41. Ogawa N., Asanuma M., Miyazaki I., Diaz‐Corrales F. J. and Miyoshi K. (2005) L‐DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson’s disease. J. Neurol. 252 (Suppl. 4), IV23–IV31.
42. Pawlyk A. C., Giasson B. I., Sampathu D. M., Perez F. A., Lim K. L., Dawson V. L., Dawson T. M., Palmiter R. D., Trojanowski J. Q. and Lee V. M.‐Y. (2003) Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J. Biol. Chem. 278, 48120–48128.
43. Petrucelli L., O’Farrell C., Lockhart P. J. et al. (2002) Parkin protects against the toxicity associated with mutant a‐synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36, 1007–1019.
44. Rosen K. M., Veereshwarayya V., Moussa C. E.‐H., Fu Q., Goldberg M. S., Schlossmacher M. G., Shen J. and Querfurth H. W. (2006) Parkin protects against mitochondrial toxins and β‐amyloid accumulation in skeletal muscle cells. J. Biol. Chem. 281, 12809–12816.
45. Sabapathy K., Hochedlinger K., Nam S. Y., Bauer A., Karin M. and Wagner E. F. (2004) Distinct roles for JNK1 and JNK2 in regulating JNK activity and c‐Jun‐dependent cell proliferation. Mol. Cell 15, 713–725.
46. Savitt J. M., Dawson V. L. and Dawson T. M. (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116, 1744–1754.
47. Shimura H., Hattori N., Kubo S. et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin‐protein ligase. Nat. Genet. 25, 302–305.
48. Silva R. M., Kuan C.‐Y., Rakic P. and Burke R. E. (2005) Mixed lineage kinase‐c‐jun N‐terminal kinase signaling pathway: a new therapeutic target in Parkinson’s disease. Mov. Disord. 20, 653–664.
49. Son J. H., Kawamata H., Yoo M. S. et al. (2005) Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons. J. Neurochem. 94, 1040–1053.
50. Sriram S. R., Li X., Ko H. S., Chung K. K. K., Wong E., Lim K. L., Dawson V. L. and Dawson T. M. (2005) Familial‐associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. Genet. 14, 2571–2586.
51. Staropoli J. F., McDermott C., Martinat C., Schulman B., Demireva E. and Abeliovich A. (2003) Parkin is a component of an SCF‐like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37, 735–749.
52. Sulzer D. (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends Neurosci. 30, 244–250.
53. Tournier C., Whitmarsh A. J., Cavanagh J., Barrett T. and Davis R. J. (1999) The MKK7 gene encodes a group of c‐Jun NH 2 ‐terminal kinase kinases. Mol. Cell. Biol. 19, 1569–1581.
54. Tsai Y. C., Fishman P. S., Thakor N. V. and Oyler G. A. (2003) Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 278, 22044–22055.
55. Vercammen L., Van der Perren A., Vaudano E., Gijsbers R., Debyser Z., Van den Haute C. and Baekelandt V. (2006) Parkin protects against neurotoxicity in the 6‐hydroxydopamine rat model for Parkinson’s disease. Mol. Ther. 14, 716–723.
56. Wang C., Tan J. M. M., Ho M. W. L., Zaiden N., Wong S. H., Chew C. L. C., Eng P. W., Lim T. M., Dawson T. M. and Lim K. L. (2005a) Alterations in the solubility and intracellular localization of parkin by several familial Parkinson’s disease‐linked point mutations. J. Neurochem. 93, 422–431.
57. Wang C., Ko H. S., Thomas B. et al. (2005b) Stress‐induced alterations in parkin solubility promote parkin aggregation and compromise parkin’s protective function. Hum. Mol. Genet. 14, 3885–3897.
58. Wang X., Destrument A. and Tournier C. (2007) Physiological roles of MKK4 and MKK7: insights from animal models. Biochim. Biophys. Acta 1773, 1349–1357.
59. Winklhofer K. F., Henn I. H., Kay‐Jackson P. C., Heller U. and Tatzelt J. (2003) Inactivation of parkin by oxidative stress and C‐terminal truncations: a protective role of molecular chaperones. J. Biol. Chem. 278, 47199–47208.
60. Wong E. S. P., Tan J. M. M., Wang C., Zhang Z., Tay S.‐P., Zaiden N., Ko H. S., Dawson V. L., Dawson T. M. and Lim K.‐L. (2007) Relative sensitivity of parkin and other cysteine‐containing enzymes to stress‐induced solubility alterations. J. Biol. Chem. 282, 12310–12318.
61. Yamada M., Mizuno Y. and Mochizuki H. (2005) Parkin gene therapy for α‐synucleinopathy: a rat model of Parkinson’s disease. Hum. Gene Ther. 16, 262–270.
62. Yamamoto A., Friedlein A., Imai Y., Takahashi R., Kahle P. J. and Haass C. (2005) Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. J. Biol. Chem. 280, 3390–3399.
63. Yang Y., Nishimura I., Imai Y., Takahashi R. and Lu B. (2003) Parkin suppresses dopaminergic neuron‐selective neurotoxicity induced by Pael‐R in Drosophila. Neuron 37, 911–924.
64. Yao D., Gu Z., Nakamura T. et al. (2004) Nitrosative stress linked to sporadic Parkinson’s disease: S‐nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl Acad. Sci. USA 101, 10810–10814.
65. Yoshimoto T., Yamamoto K. and Tsuru D. (1985) Extracellular tyrosinase from Streptomyces sp. KY‐453: purification and some enzymatic properties. J. Biochem. 97, 1747–1754.
66. Zhang Y., Gao J., Chung K. K. K., Huang H., Dawson V. L. and Dawson T. M. (2000) Parkin functions as an E2‐dependent ubiquitin‐protein ligase and promotes the degradation of the synaptic vesicle‐associated protein, CDCrel‐1. Proc. Natl Acad. Sci. USA 97, 13354–13359.